Aktien

4. Impfstoff-Montag in Folge: Moderna beantrag Zulassung, Aktie +11 Prozent

Arzt mit Spritze

Die letzten drei Montage gab es immer Mittags zu deutscher Zeit von Pharmafirmen Erfolgsmeldungen zum jeweils eigenen Corona-Impfstoff. Jedes Mal gab es einen positiven Effekt auf die Aktienmärkte. Am 16. November war das US-Pharmaunternehmen Moderna an der Reihe mit eine positiven Meldung über den eigenen Wirkstoff. Heute zwei Wochen später hat Moderna vor wenigen Minuten eine weitere Meldung veröffentlicht, welche die Aktie vorbörslich in New York um 11 Prozent in die Gewinnzone befördert.

Man will eine Notfall-Zulassung bei der US-amerikanischen Arzneimittelbehörde FDA beantragen. Und noch wichtiger, als erstes Pharmaunternehmen will Moderna jetzt die Zulassung für einen Corona-Impfstoff in der EU beantragen. Der Moderna-Antrag auf eine „bedingte Zulassung“ solle noch heute bei der Europäischen Arzneimittel-Agentur „EMA“ gestellt werden. Hier auch soeben veröffentlichte Detailaussagen von Moderna zum eigenen Corona-Impfstoff, im Wortlaut:

The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. Vaccine efficacy has been demonstrated at the first interim analysis with a total of 95 cases based on the pre-specified success criterion on efficacy. Today’s primary analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.1%. A secondary endpoint analyzed severe cases of COVID-19 and included 30 severe cases (as defined in the study protocol) in this analysis. All 30 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. There was one COVID-19-related death in the study to date, which occurred in the placebo group.

Efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants).

The safety profile of the Phase 3 study of mRNA-1273 was previously described on November 16. A continuous review of safety data is ongoing and no new serious safety concerns have been identified by the Company. Based on prior analysis, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.

The Company will submit data from the Phase 3 COVE study to a peer-reviewed publication.

“This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, as well as the staff at clinical trial sites who have been on the front lines of the fight against the virus. I would again like to thank our partners at NIH, NIAID, BARDA and Operation Warp Speed who have helped us advance the clinical development of mRNA-1273. Finally, I want to thank the Moderna team and our suppliers and partners for their tireless work on the research, development and manufacturing of our vaccine. We will file today for an Emergency Use Authorization from the FDA and continue forging ahead with the rolling reviews that have already been initiated with several regulatory agencies around the globe.”

Chart zeigt Verlauf der Moderna-Aktie seit Ende 2019



Kommentare lesen und schreiben, hier klicken

Lesen Sie auch

Hinterlassen Sie eine Antwort

Ihre E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert.




ACHTUNG: Wenn Sie den Kommentar abschicken stimmen Sie der Speicherung Ihrer Daten zur Verwendung der Kommentarfunktion zu.
Weitere Information finden Sie in unserer Zur Datenschutzerklärung

Meist gelesen 7 Tage